Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors

References

• Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007;12(3–4):112–124. doi:10.1016/j.drudis.2006.12.00817275731
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi:10.1016/j.cell.2006.01.01616469695
   PubMed Web of Science ®Google Scholar
• Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer. 2009;115(10):2313–2320. doi:10.1002/cncr.2423919402072
   PubMed Web of Science ®Google Scholar
• Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med. 2011;52(4):497–500. doi:10.2967/jnumed.111.08962321421716
   PubMed Web of Science ®Google Scholar
• Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98(18):10314–10319. doi:10.1073/pnas.17107679811504908
   PubMed Web of Science ®Google Scholar
• Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ± mice. Proc Natl Acad Sci USA. 2001;98(18):10320–10325. doi:10.1073/pnas.17106009811504907
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596–603. doi:10.1016/j.ceb.2005.09.00916226444
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc83912094235
   PubMed Web of Science ®Google Scholar
• Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010;29(18):2746–2752. doi:10.1038/onc.2010.2820190810
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–1101. doi:10.1126/science.110614815718470
   PubMed Web of Science ®Google Scholar
• Ma L, Teruya-Feldstein J, Behrendt N, et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 2005;19(15):1779–1786. doi:10.1101/gad.131440516027168
   PubMed Web of Science ®Google Scholar
• Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 2005;19(15):1773–1778. doi:10.1101/gad.131460516027169
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature1222223792563
   PubMed Web of Science ®Google Scholar
• Hager M, Haufe H, Lusuardi L, Schmeller N, Kolbitsch C. PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest. 2011;29(7):427–438. doi:10.3109/07357907.2011.58478221696297
   PubMed Web of Science ®Google Scholar
• Cargnello M, Tcherkezian J, Roux PP. The expanding role of mTOR in cancer cell growth and proliferation. Mutagenesis. 2015;30(2):169–176. doi:10.1093/mutage/geu04525688110
   PubMed Web of Science ®Google Scholar
• Guo H, German P, Bai S, et al. The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics. 2015;42(7):343–353. doi:10.1016/j.jgg.2015.03.00326233890
   PubMed Web of Science ®Google Scholar
• Han G, Zhao W, Song X, et al. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics. 2017;18(6):678. doi:10.1186/s12864-017-4026-628984208
   PubMed Web of Science ®Google Scholar
• Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn’t, and what the future holds. Clin Genitourin Cancer. 2021;19(2):103–116. doi:10.1016/j.clgc.2020.11.00533358151
   PubMed Web of Science ®Google Scholar
• Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34(6):1167–1184. doi:10.1038/s41379-021-00737-633526874
   PubMed Web of Science ®Google Scholar
• Fan D, Liu Q, Wu F, et al. Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. PeerJ. 2020;8:e9261. doi:10.7717/peerj.926132547875
   PubMed Web of Science ®Google Scholar
• Ocana A, Vera-Badillo F, Al-Mubarak M, et al. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014;9(4):e95219. doi:10.1371/journal.pone.009521924777052
   PubMed Web of Science ®Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797. doi:10.1136/bmj.g479725385470
   PubMed Web of Science ®Google Scholar
• Linehan WM, Rathmell WK. Kidney cancer. Urol Oncol. 2012;30(6):948–951. doi:10.1016/j.urolonc.2012.08.02123218074
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996;58(5):373–395. doi:10.1016/0024-3205(95)02233-38594303
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412–1418. doi:10.1200/JCO.2013.50.826724687826
   PubMed Web of Science ®Google Scholar
• Ghidini M, Petrelli F, Ghidini A, et al. Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs. 2017;26(11):1229–1237. doi:10.1080/13543784.2017.1384813
   PubMed Web of Science ®Google Scholar
• Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003;63(3):917–926. doi:10.1046/j.1523-1755.2003.00805.x12631072
   PubMed Web of Science ®Google Scholar
• Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A Phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115(11):2438–2446. doi:10.1002/cncr.2428019306412
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456. doi:10.1016/S0140-6736(08)61039-918653228
   PubMed Web of Science ®Google Scholar
• Ravaud A, Barrios CH, Alekseev B, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1378–1384. doi:10.1093/annonc/mdv17025851632
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772. doi:10.1200/JCO.2013.54.691125049330
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, Phase 3 trial. Lancet Oncol. 2016;17(7):917–927. doi:10.1016/S1470-2045(16)30107-327279544
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156–4167. doi:10.1002/cncr.3303332673417
   PubMed Web of Science ®Google Scholar
• Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–235. doi:10.1016/j.ejca.2016.08.00427680407
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–388. doi:10.1016/S1470-2045(15)00515-X26794930
   PubMed Web of Science ®Google Scholar
• Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–874. doi:10.1016/j.eururo.2015.10.04926626617
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281. doi:10.1056/NEJMoa06683817538086
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760–767. doi:10.1200/JCO.2013.50.396124297950
   PubMed Web of Science ®Google Scholar
• Bergmann L, Grünwald V, Maute L, et al. A randomized phase iia trial with temsirolimus versus sunitinib in advanced non-clear cell renal cell carcinoma: an intergroup study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on renal cell cancer (IAGN) of the German cancer society. Oncol Res Treat. 2020;43(7–8):333–339.32541143
   PubMed Web of Science ®Google Scholar
• Voss MH, Hakimi AA, Pham CG, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res. 2014;20(7):1955–1964. doi:10.1158/1078-0432.CCR-13-234524622468
   PubMed Web of Science ®Google Scholar
• Roldan-Romero JM, Beuselinck B, Santos M, et al. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. Int J Cancer. 2020;146(5):1435–1444. doi:10.1002/ijc.3257931335987
   PubMed Web of Science ®Google Scholar
• Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(10):2445–2452. doi:10.1158/1078-0432.CCR-15-263126831717
   PubMed Web of Science ®Google Scholar
• Adib E, Klonowska K, Giannikou K, et al. Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations. Clin Cancer Res. 2021;27(14):3845–3853. doi:10.1158/1078-0432.CCR-20-454833727259
   PubMed Web of Science ®Google Scholar
• Basu B, Dean E, Puglisi M, et al. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015;21(15):3412–3419. doi:10.1158/1078-0432.CCR-14-242225805799
   PubMed Web of Science ®Google Scholar
• White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182(3):396–403. doi:10.1164/rccm.200911-1720OC20194812
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159–168. doi:10.1016/j.molcel.2006.03.02916603397
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009;29(21):5657–5670. doi:10.1128/MCB.00735-0919720745
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–1508. doi:10.1158/0008-5472.CAN-05-292516452206
   PubMed Web of Science ®Google Scholar
• Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332(6035):1322–1326. doi:10.1126/science.119948421659605
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166(2):213–223. doi:10.1083/jcb.20040306915249583
   PubMed Web of Science ®Google Scholar
• Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E. Targeting HIF-2 α in clear cell renal cell carcinoma: a promising therapeutic strategy. Crit Rev Oncol Hematol. 2017;111:117–123. doi:10.1016/j.critrevonc.2017.01.01328259286
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein. Nat Cell Biol. 2000;2(7):423–427. doi:10.1038/3501705410878807
   PubMed Web of Science ®Google Scholar
• Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol. 2009;41(4):753–756. doi:10.1016/j.biocel.2008.09.02418950731
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2. J Biol Chem. 2008;283(50):34495–34499. doi:10.1074/jbc.C80017020018945681
   PubMed Web of Science ®Google Scholar
• Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1(3):E83. doi:10.1371/journal.pbio.000008314691554
   PubMed Web of Science ®Google Scholar
• Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002;1(3):247–255. doi:10.1016/S1535-6108(02)00044-212086861
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22. doi:10.1016/j.ccr.2007.05.00817613433
   PubMed Web of Science ®Google Scholar
• Evans AJ, Russell RC, Roche O, et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol. 2007;27(1):157–169. doi:10.1128/MCB.00892-0617060462
   PubMed Web of Science ®Google Scholar
• Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59(4):886–894.10029080
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Medina EC, Esquivel JA, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010;16(1):141–153. doi:10.1158/1078-0432.CCR-09-138520028765
   PubMed Web of Science ®Google Scholar
• Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–183.11294822
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065–3074.18725988
   PubMed Web of Science ®Google Scholar
• Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci. 2020;77(22):4459–4483.32358622
   PubMed Web of Science ®Google Scholar
• Hervouet E, Simonnet H, Godinot C. Mitochondria and reactive oxygen species in renal cancer. Biochimie. 2007;89(9):1080–1088. doi:10.1016/j.biochi.2007.03.01017466430
   PubMed Web of Science ®Google Scholar
• Okoh VO, Felty Q, Parkash J, Poppiti R, Roy D. Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells. PLoS One. 2013;8(2):e54206. doi:10.1371/journal.pone.005420623437041
   PubMed Web of Science ®Google Scholar
• Basu A, Sridharan S, Persaud S. Regulation of protein kinase C delta downregulation by protein kinase C epsilon and mammalian target of rapamycin complex 2. Cell Signal. 2009;21(11):1680–1685. doi:10.1016/j.cellsig.2009.07.00619632318
   PubMed Web of Science ®Google Scholar
• Wu WS, Tsai RK, Chang CH, Wang S, Wu JR, Chang YX. Reactive oxygen species mediated sustained activation of protein kinase C alpha and extracellular signal-regulated kinase for migration of human hepatoma cell Hepg2. Mol Cancer Res. 2006;4(10):747–758. doi:10.1158/1541-7786.MCR-06-009617050668
   PubMed Web of Science ®Google Scholar
• Hervouet E, Cízková A, Demont J, et al. HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis. 2008;29(8):1528–1537. doi:10.1093/carcin/bgn12518515279
   PubMed Web of Science ®Google Scholar
• Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010;22(2):132–139. doi:10.1016/j.ceb.2009.12.00420056399
   PubMed Web of Science ®Google Scholar
• Jung CH, Jun CB, Ro SH, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009;20(7):1992–2003. doi:10.1091/mbc.e08-12-124919225151
   PubMed Web of Science ®Google Scholar
• Bray K, Mathew R, Lau A, et al. Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One. 2012;7(7):e41831. doi:10.1371/journal.pone.004183122848625
   PubMed Web of Science ®Google Scholar
• Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One. 2009;4(6):e5994. doi:10.1371/journal.pone.000599419543393
   PubMed Web of Science ®Google Scholar
• Deleuze A, Saout J, Dugay F, et al. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci. 2020;21(7):2532. doi:10.3390/ijms21072532
   PubMed Web of Science ®Google Scholar
• Santoni M, De Giorgi U, Iacovelli R, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;109(7):1755–1759. doi:10.1038/bjc.2013.52224008663
   PubMed Web of Science ®Google Scholar
• Holdaas H, De Simone P, Zuckermann A. Everolimus and malignancy after solid organ transplantation: a clinical update. J Transplant. 2016;2016:4369574. doi:10.1155/2016/436957427807479
   PubMedGoogle Scholar
• Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Curr Top Microbiol Immunol. 2010;347:241–262.20549474
   PubMed Web of Science ®Google Scholar
• Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38. doi:10.1371/journal.pbio.100003819209957
   PubMed Web of Science ®Google Scholar
• Powles T, Wheater M, Din O, et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur Urol. 2016;69(3):450–456. doi:10.1016/j.eururo.2015.08.03526364551
   PubMed Web of Science ®Google Scholar
• Voss MH, Gordon MS, Mita M, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020;123(11):1590–1598. doi:10.1038/s41416-020-01041-x32913286
   PubMed Web of Science ®Google Scholar
• Rodrik-Outmezguine VS, Okaniwa M, Yao Z, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534(7606):272–276. doi:10.1038/nature1796327279227
   PubMed Web of Science ®Google Scholar
• Kuroshima K, Yoshino H, Okamura S, et al. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. Cancer Sci. 2020;111(5):1607–1618. doi:10.1111/cas.1439532232883
   PubMed Web of Science ®Google Scholar
• Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118(7):1868–1876. doi:10.1002/cncr.2642921898375
   PubMed Web of Science ®Google Scholar
• Kanesvaran R, Watt K, Turnbull JD, et al. A single-arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2015;13(4):319–327. doi:10.1016/j.clgc.2014.12.01126174223
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi:10.1016/S1470-2045(15)00290-926482279
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi:10.1056/NEJMoa203571633616314
   PubMed Web of Science ®Google Scholar
• Hutson TE, Michaelson MD, Kuzel TM, et al. A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2021;80(2):162–170. doi:10.1016/j.eururo.2021.03.01533867192
   PubMed Web of Science ®Google Scholar
• Bitting RL, Healy P, Creel PA, et al. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014;12(4):241–250. doi:10.1016/j.clgc.2013.11.02024685058
   PubMed Web of Science ®Google Scholar
• Zhu M, Molina JR, Dy GK, et al. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors. Invest New Drugs. 2020;38(6):1755–1762. doi:10.1007/s10637-020-00936-z32328844
   PubMed Web of Science ®Google Scholar
• Sheng X, Yan X, Chi Z, et al. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine. 2020;55:102755. doi:10.1016/j.ebiom.2020.10275532335374
   PubMed Web of Science ®Google Scholar
• Pedersen KS, Grierson PM, Picus J, et al. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study. Invest New Drugs. 2021;39(5):1298–1305. PMID: 33738668. doi:10.1007/s10637-021-01093-733738668
   PubMed Web of Science ®Google Scholar
• Davis ID, Long A, Yip S, et al. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Ann Oncol. 2015;26(6):1118–1123. doi:10.1093/annonc/mdv07825701452
   PubMed Web of Science ®Google Scholar
• Cirkel GA, Hamberg P, Sleijfer S, et al. Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: the ROPETAR randomized clinical trial. JAMA Oncol. 2017;3(4):501–508. doi:10.1001/jamaoncol.2016.520227918762
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vida A, Bamias A, Esteban E, et al. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). BJU Int. 2020;126(5):559–567. doi:10.1111/bju.1516532654362
   PubMed Web of Science ®Google Scholar
• Carlo MI, Molina AM, Lakhman Y, et al. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist. 2016;21(7):787–788. doi:10.1634/theoncologist.2016-014527286790
   PubMed Web of Science ®Google Scholar
• Powles T, Lackner MR, Oudard S, et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2016;34(14):1660–1668. doi:10.1200/JCO.2015.64.880826951309
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–784. doi:10.1038/nrd213316955068
   PubMed Web of Science ®Google Scholar
• Zibelman M, Wong YN, Devarajan K, et al. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs. 2015;33(5):1040–1047. doi:10.1007/s10637-015-0261-326091915
   PubMed Web of Science ®Google Scholar
• Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Invest New Drugs. 2020;38(4):1108–1116. doi:10.1007/s10637-019-00864-731654285
   PubMed Web of Science ®Google Scholar
• Yang YP, Hu LF, Zheng HF, et al. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin. 2013;34(5):625–635. doi:10.1038/aps.2013.523524572
   PubMed Web of Science ®Google Scholar
• Haas NB, Appleman LJ, Stein M, et al. Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. Clin Cancer Res. 2019;25(7):2080–2087. doi:10.1158/1078-0432.CCR-18-220430635337
   PubMed Web of Science ®Google Scholar